Audentes Therapeutics Inc (NASDAQ:BOLD) Shares Bought by Rhumbline Advisers

Rhumbline Advisers raised its position in Audentes Therapeutics Inc (NASDAQ:BOLD) by 1.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 61,051 shares of the biotechnology company’s stock after buying an additional 1,070 shares during the period. Rhumbline Advisers owned about 0.13% of Audentes Therapeutics worth $1,715,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of BOLD. BlackRock Inc. boosted its holdings in Audentes Therapeutics by 14.2% in the 2nd quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock worth $126,204,000 after buying an additional 413,768 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Audentes Therapeutics by 118.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 592,947 shares of the biotechnology company’s stock worth $22,449,000 after buying an additional 321,756 shares during the last quarter. Nuveen Asset Management LLC acquired a new stake in Audentes Therapeutics in the 2nd quarter worth about $8,653,000. Eversept Partners LP acquired a new stake in Audentes Therapeutics in the 2nd quarter worth about $6,040,000. Finally, Morgan Stanley boosted its holdings in Audentes Therapeutics by 1,838.1% in the 2nd quarter. Morgan Stanley now owns 164,429 shares of the biotechnology company’s stock worth $6,225,000 after buying an additional 155,945 shares during the last quarter. Institutional investors own 98.46% of the company’s stock.

BOLD has been the topic of a number of research reports. Robert W. Baird initiated coverage on shares of Audentes Therapeutics in a research note on Wednesday, October 2nd. They issued an “underperform” rating and a $10.00 target price on the stock. ValuEngine lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Zacks Investment Research lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Evercore ISI reissued a “hold” rating and issued a $34.00 target price on shares of Audentes Therapeutics in a research note on Monday. Finally, Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Audentes Therapeutics in a research note on Sunday, October 6th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. Audentes Therapeutics currently has an average rating of “Hold” and an average price target of $40.28.

BOLD opened at $25.83 on Friday. The company’s 50 day simple moving average is $27.72 and its two-hundred day simple moving average is $34.03. Audentes Therapeutics Inc has a 1-year low of $17.95 and a 1-year high of $41.65.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.07. During the same quarter in the previous year, the business posted ($0.97) EPS. Sell-side analysts forecast that Audentes Therapeutics Inc will post -4.13 EPS for the current fiscal year.

In other news, Director Louis G. Lange sold 10,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $32.16, for a total transaction of $321,600.00. Following the sale, the director now owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $30.00, for a total transaction of $432,780.00. Following the sale, the chief executive officer now directly owns 127,820 shares in the company, valued at approximately $3,834,600. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by insiders.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: Why is insider trading harmful?

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.